Prostate Cancer Risk Assessment
Prostate cancer is the most common type of cancer diagnosed in Australian men. Statistical data from the Australian Cancer Research Foundation showed that the risk of developing prostate cancer before the age of 85 is 1 in 5 men. This is why it is crucial to obtain a comprehensive prostate cancer assessment from a trusted urologist to detect possible signs of the condition and receive immediate treatment to ease its onset.
Today, technological advancement has paved the way for a new genomic test referred to as the Oncotype DX prostate cancer test (assay). This test helps determine how aggressive the cancer is, thereby helping doctors and patients to individualise or personalise their course of treatment.
Increased understanding of how gene expression profiles can predict the risk associated with a particular cancer has allowed the development of a Genomic Prostate Score. This is a 17 gene signature analysis that gives a sophisticated prediction of the likely biological behaviour of your particular prostate cancer. That is based on the genes expressed by the cells in your biopsy sample. With the use of this method, it is possible to predict the behaviour of your illness over time, whether it will progress and whether you will benefit from treatment.
Gene signature analysis has been used in breast cancer patients for a number of years and will be increasingly relevant to the management of prostate cancer in men, particularly those with equivocal biopsy results where the decision to undergo active surveillance versus active management is difficult.
Get Efficient & Accurate Prostate Cancer Risk Assessment at Katelaris
Dr Katelaris has developed a liaison with the central laboratory in the United States performing the gene analysis and if it is recommended to you, you can opt for genetic testing to aid your decision with respect to management.
Learn more about genomic prostate cancer test and other types of urological treatments and procedures, consult our internationally recognised urologist, Dr Phillip Katelaris.
You can also visit these websites to learn more about genomic prostate score: